What is PHAR's current stock price?

PHAR (Pharming Group N.V.) is currently trading at $12.60 with a market cap of $889.9M.

What sector is Pharming Group N.V. in?

Pharming Group N.V. (PHAR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PHAR a good stock to buy?

Analysts have a Buy consensus on PHAR with a price target of $38.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PHAR Pharming Group N.V.

Healthcare

$12.60-1.64%ClosedMarket Cap: $889.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

386.59

PEG

3.12

P/B

3.83

P/S

2.65

EV/EBITDA

30.85

DCF Value

$12.10

FCF Yield

5.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

88.1%

Operating Margin

6.4%

Net Margin

3.4%

ROE

4.7%

ROA

2.5%

ROIC

3.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$72.7M	$-5.2M	$—
Q4 null	$106.50B	$5.30B	$—
FY null	$377.2M	$2.9M	$—
Q3 null	$97.3M	$7.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$38.00

Target (Median)

$37.00

Target Range

$37.00 - $40.00

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-24

OppenheimerOutperform

2026-03-13

Trading Activity

Insider Trades

View All

CAMDEN PARTNERS STRATEGIC FUND II A LPother: See General Remarks and FN 1

SellMon Jul 12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.12

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Peers